[size=0.875]ReviewVolume 25, Issue 8p764-780August 2026Download Full Issue
The role of the gut microbiome in mediating neuroinflammation in immune-based neurological disordersClaude Steriade, MDCM[url=]a[/url],[url=]b[/url] Send email to [email protected] ∙ Prof Nicola Segata, PhD[url=]c[/url] ∙ Prof Deepak Saxena, PhD[url=]d[/url] Send email to [email protected]
Affiliations & Notes
Article InfoPublication History:
Published August 2026
DOI: 10.1016/S1474-4422(26)00193-6 External LinkAlso available on ScienceDirect External Link
Copyright: © 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
- [color=inherit !important]Get Access
- [url=https://www.thelancet.com/action/showCitFormats?doi=10.1016%2FS1474-4422%2826%2900193-6&pii=S1474-4422%2826%2900193-6][size=1.3]Cite
- [size=1.3]Share
- [size=1.3]Set Alert
- [size=1.3]Get Rights
- [size=1.3]Reprints
[size=1.3]
[size=1.3]Previous articleNext article[size=1.3]
Show Outline
SummaryThe gut microbiome can influence brain health by modulating neuroinflammation through various mechanisms, including immune regulation, the production of metabolites that affect neural function, gut and blood每brain barrier integrity, upstream effects via the vagus nerve, upstream migration of gut-resident lymphocytes to the brain, bile acid signalling, and endocrine activity. Changes in gut microbiota have been observed in demyelinating conditions, autoimmune encephalitis, and epilepsy. Gut microbiota composition changes can affect neuroinflammation, disease progression, and treatment outcomes. Advances in microbiome research have improved the potential for clinical translation of findings; but limitations persist, driven by the largely correlational nature of clinical studies and the complexity of microbiome sequencing and interpretation. At present, only the ketogenic diet is routinely recommended by clinicians, whereas other microbiome-based interventions remain investigational. Multiple strategies for manipulating the gut microbiome, including dietary changes, prebiotics, probiotics, postbiotics, and faecal microbiota transplantation, might be used as disease-modifying therapies in the future.
[/url]
Get full text access[size=1.125]Log in, subscribe or purchase for full access. [color=inherit !important]Get Access
References1.
Shi, FD ∙ Yong, VW
Neuroinflammation across neurological diseases
Science. 2025; 388, eadx0043
[url=https://doi.org/10.1126/science.adx0043]Crossref
Scopus (22)
Google Scholar
2.
Miller, JW
Inflammation as a target for epilepsy therapy: the case of natalizumab
Neurology. 2021; 97:845-846
Crossref
Scopus (10)
PubMed
Google Scholar
3.
Cryan, JF ∙ O'Riordan, KJ ∙ Sandhu, K ∙ et al.
The gut microbiome in neurological disorders
Lancet Neurol. 2020; 19:179-194
Full Text
Full Text (PDF)
Scopus (710)
PubMed
Google Scholar
4.
Morais, LH ∙ Schreiber, 4th, HL ∙ Mazmanian, SK
The gut microbiota每brain axis in behaviour and brain disorders
Nat Rev Microbiol. 2021; 19:241-255
Crossref
Scopus (954)
PubMed
Google Scholar
5.
Asnicar, F ∙ Manghi, P ∙ Fackelmann, G ∙ et al.
Gut micro-organisms associated with health, nutrition and dietary interventions
Nature. 2026; 650:450-458
Crossref
Scopus (4)
PubMed
Google Scholar
6.
Asnicar, F ∙ Berry, SE ∙ Valdes, AM ∙ et al.
Microbiome connections with host metabolism and habitual diet from 1,098 deeply phenotyped individuals
Nat Med. 2021; 27:321-332
Crossref
Scopus (466)
PubMed
Google Scholar
7.
Ley, R
The human microbiome: there is much left to do
Nature. 2022; 606:435
Crossref
Scopus (11)
PubMed
Google Scholar
8.
Boutitah-Benyaich, I ∙ Eixarch, H ∙ Villacieros-Álvarez, J ∙ et al.
Multiple sclerosis: molecular pathogenesis and therapeutic intervention
Signal Transduct Target Ther. 2025; 10:324
Crossref
Scopus (56)
PubMed
Google Scholar
9.
Cheng, X ∙ Li, Y ∙ Wang, Y ∙ et al.
Impact of blood每brain barrier disruption on clinical features and treatment response in patients with newly diagnosed autoimmune encephalitis
J Neuroimmunol. 2023; 383, 578203
Full Text
Full Text (PDF)
Scopus (10)
Google Scholar
10.
Cafri, N ∙ Mirloo, S ∙ Zarhin, D ∙ et al.
Imaging blood每brain barrier dysfunction in drug-resistant epilepsy: a multi-center feasibility study
Epilepsia. 2025; 66:195-206
Crossref
Scopus (8)
Google Scholar
11.
Cudna, A ∙ Bronisz, E ∙ Jopowicz, A ∙ et al.
Changes in serum blood每brain barrier markers after bilateral tonic每clonic seizures
Seizure. 2023; 106:129-137
Full Text
Full Text (PDF)
Scopus (0)
PubMed
Google Scholar
12.
Ivens, S ∙ Kaufer, D ∙ Flores, LP ∙ et al.
TGF-beta receptor-mediated albumin uptake into astrocytes is involved in neocortical epileptogenesis
Brain. 2007; 130:535-547
Crossref
Scopus (444)
PubMed
Google Scholar
13.
Mazarati, A ∙ Medel-Matus, JS ∙ Shin, D ∙ et al.
Disruption of intestinal barrier and endotoxemia after traumatic brain injury: implications for post-traumatic epilepsy
Epilepsia. 2021; 62:1472-1481
Crossref
Scopus (20)
PubMed
Google Scholar
14.
Su, Y ∙ Zheng, H ∙ Shi, C ∙ et al.
Meningeal immunity and neurological diseases: new approaches, new insights
J Neuroinflammation. 2023; 20:125
Crossref
Scopus (14)
PubMed
Google Scholar
15.
Xu, H ∙ Hehnly, C ∙ Lehtinen, MK
The choroid plexus: a command center for brain每body communication during inflammation
Curr Opin Immunol. 2025; 93, 102540
Crossref
Scopus (6)
PubMed
Google Scholar
16.
Zou, K ∙ Deng, Q ∙ Zhang, H ∙ et al.
Glymphatic system: a gateway for neuroinflammation
Neural Regen Res. 2024; 19:2661-2672
Crossref
Scopus (63)
PubMed
Google Scholar
17.
Wesselingh, R ∙ Griffith, S ∙ Ko, K ∙ et al., the Australian Autoimmune Encephalitis Consortium
Biomarkers of neuroaxonal and astrocytic pathology in autoimmune encephalitis
Brain Behav Immun. 2026; 132, 106206
Crossref
Scopus (2)
PubMed
Google Scholar
18.
Stadelmann, C ∙ Franz, J ∙ Nessler, S
Recent developments in multiple sclerosis neuropathology
Curr Opin Neurol. 2025; 38:173-179
Crossref
Scopus (3)
PubMed
Google Scholar
19.
Kovbasyuk, Z ∙ Tefera, E ∙ Li, C ∙ et al.
Imaging brain inflammation and blood brain barrier permeability in neurological and psychiatric diseases: a review
J Neuroinflammation. 2025; 22:275
Crossref
Scopus (6)
PubMed
Google Scholar
20.
Villasana-Salazar, B ∙ Vezzani, A
Neuroinflammation microenvironment sharpens seizure circuit
Neurobiol Dis. 2023; 178, 106027
Crossref
Scopus (19)
PubMed
Google Scholar
21.
Vezzani, A ∙ Balosso, S ∙ Ravizza, T
Neuroinflammatory pathways as treatment targets and biomarkers in epilepsy
Nat Rev Neurol. 2019; 15:459-472
Crossref
Scopus (500)
PubMed
Google Scholar
22.
Ramos, AJ ∙ Lazarowski, A ∙ Vega-Garc赤a, A ∙ et al.
Modulation of neuroinflammation as a therapeutic strategy for the control of epilepsy
Seizure. 2025; 131:458-470
Full Text
Full Text (PDF)
Scopus (0)
PubMed
Google Scholar
23.
Hu, A ∙ Yuan, H ∙ Qin, Y ∙ et al.
Lipopolysaccharide (LPS) increases susceptibility to epilepsy via interleukin-1 type 1 receptor signaling
Brain Res. 2022; 1793, 148052
Crossref
Scopus (11)
PubMed
Google Scholar
24.
Steriade, C ∙ Titulaer, MJ ∙ Vezzani, A ∙ et al.
The association between systemic autoimmune disorders and epilepsy and its clinical implications
Brain. 2021; 144:372-390
Crossref
Scopus (58)
PubMed
Google Scholar
25.
Huang, X ∙ Hussain, B ∙ Chang, J
Peripheral inflammation and blood每brain barrier disruption: effects and mechanisms
CNS Neurosci Ther. 2021; 27:36-47
Crossref
Scopus (0)
PubMed
Google Scholar
26.
Lopes Fischer, N ∙ Naseer, N ∙ Shin, S ∙ et al.
Effector-triggered immunity and pathogen sensing in metazoans
Nat Microbiol. 2020; 5:14-26
Crossref
Scopus (73)
PubMed
Google Scholar
27.
Theodore, WH ∙ Leibovitch, E ∙ Billioux, BJ ∙ et al.
Human herpesvirus 6 and epilepsy
Epilepsia Open. 2021; 6:777-780
Crossref
Scopus (9)
PubMed
Google Scholar
28.
Frau, J ∙ Coghe, G ∙ Lorefice, L ∙ et al.
The role of microorganisms in the etiopathogenesis of demyelinating diseases
Life. 2023; 13, 1309
Crossref
Scopus (20)
PubMed
Google Scholar
29.
Ishijima, T ∙ Nakajima, K
Inflammatory cytokines TNF汐, IL-1汕, and IL-6 are induced in endotoxin-stimulated microglia through different signaling cascades
Sci Prog. 2021; 104
368504211054985
Crossref
Scopus (107)
PubMed
Google Scholar
30.
White, Z ∙ Cabrera, I ∙ Mei, L ∙ et al.
Gut inflammation promotes microbiota-specific CD4 T cell-mediated neuroinflammation
Nature. 2025; 643:509-518
Crossref
Scopus (1)
PubMed
Google Scholar
31.
Yoshida, TM ∙ Nguyen, M ∙ Zhang, L ∙ et al.
The subfornical organ is a nucleus for gut-derived T cells that regulate behaviour
Nature. 2025; 643:499-508
Crossref
Scopus (2)
PubMed
Google Scholar
32.
Rahmani, D ∙ Chodari, L ∙ Kakallahpour, M ∙ et al.
Therapeutic potential of sodium butyrate in neurological and psychiatric disorders
Mol Neurobiol. 2026; 63:90
Crossref
Scopus (2)
Google Scholar
33.
Kearns, R
Gut每brain axis and neuroinflammation: the role of gut permeability and the kynurenine pathway in neurological disorders
Cell Mol Neurobiol. 2024; 44:64
Crossref
Scopus (7)
PubMed
Google Scholar
34.
Yan, J ∙ Kothur, K ∙ Mohammad, S ∙ et al.
CSF neopterin, quinolinic acid and kynurenine/tryptophan ratio are biomarkers of active neuroinflammation
eBioMedicine. 2023; 91, 104589
Full Text
Full Text (PDF)
Scopus (16)
PubMed
Google Scholar
35.
Seo, SK ∙ Kwon, B
Immune regulation through tryptophan metabolism
Exp Mol Med. 2023; 55:1371-1379
Crossref
Scopus (15)
PubMed
Google Scholar
36.
Mou, Y ∙ Du, Y ∙ Zhou, L ∙ et al.
Gut microbiota interact with the brain through systemic chronic inflammation: implications on neuroinflammation, neurodegeneration, and aging
Front Immunol. 2022; 13, 796288
Crossref
Scopus (185)
Google Scholar
37.
Gargus, M ∙ Ben-Azu, B ∙ Landwehr, A ∙ et al.
Mechanisms of vagus nerve stimulation for the treatment of neurodevelopmental disorders: a focus on microglia and neuroinflammation
Front Neurosci. 2025; 18, 1527842
Crossref
Scopus (24)
PubMed
Google Scholar
38.
Muller, PA ∙ Schneeberger, M ∙ Matheis, F ∙ et al.
Microbiota modulate sympathetic neurons via a gut每brain circuit
Nature. 2020; 583:441-446
Crossref
Scopus (231)
PubMed
Google Scholar
39.
Fogelson, KA ∙ Dorrestein, PC ∙ Zarrinpar, A ∙ et al.
The gut microbial bile acid modulation and its relevance to digestive health and diseases
Gastroenterology. 2023; 164:1069-1085
Full Text
Full Text (PDF)
Scopus (21)
PubMed
Google Scholar
40.
Bhargava, P ∙ Smith, MD ∙ Mische, L ∙ et al.
Bile acid metabolism is altered in multiple sclerosis and supplementation ameliorates neuroinflammation
J Clin Invest. 2020; 130:3467-3482
Crossref
Scopus (112)
PubMed
Google Scholar
41.
Li, X ∙ Ji, J ∙ Li, J ∙ et al.
Gut microbiota-bile acid metabolic disorder involved in the cognitive impairments in epilepsy through HO-1 dependent ferroptosis
J Pharm Anal. 2025; 15, 101291
Crossref
Scopus (6)
Google Scholar
42.
Tofani, GSS ∙ Leigh, SJ ∙ Gheorghe, CE ∙ et al.
Gut microbiota regulates stress responsivity via the circadian system
Cell Metab. 2025; 37:138-153
Full Text
Full Text (PDF)
Scopus (0)
PubMed
Google Scholar
43.
Wang, J ∙ Liu, S ∙ Xie, Y ∙ et al.
Association analysis of gut microbiota-metabolites-neuroendocrine changes in male rats acute exposure to simulated altitude of 5500 m
Sci Rep. 2023; 13, 9225
Google Scholar
44.
Zhao, Q ∙ Chen, Y ∙ Huang, W ∙ et al.
Drug每microbiota interactions: an emerging priority for precision medicine
Signal Transduct Target Ther. 2023; 8:386
Crossref
Scopus (230)
PubMed
Google Scholar
45.
Zhang, Y ∙ Mo, C ∙ Ai, P ∙ et al.
Pharmacomicrobiomics: a new field contributing to optimizing drug therapy in Parkinson's disease
Gut Microbes. 2025; 17, 2454937
Crossref
Scopus (17)
Google Scholar
46.
Vich Vila, A ∙ Collij, V ∙ Sanna, S ∙ et al.
Impact of commonly used drugs on the composition and metabolic function of the gut microbiota
Nat Commun. 2020; 11:362
Crossref
Scopus (422)
PubMed
Google Scholar
47.
Dop, C ∙ Auvin, S ∙ Mondot, S ∙ et al.
Longitudinal exposure to antiseizure medications shape gut-derived microbiome, resistome, and metabolome landscape
ISME Commun. 2024; 4, ycae123
Crossref
Scopus (0)
PubMed
Google Scholar
48.
Ilhan, ZE ∙ Brochard, V ∙ Lapaque, N ∙ et al.
Exposure to anti-seizure medications impact growth of gut bacterial species and subsequent host response
Neurobiol Dis. 2022; 167, 105664
Crossref
Scopus (20)
PubMed
Google Scholar
49.
Dodd, D ∙ Cann, I
Tutorial: microbiome studies in drug metabolism
Clin Transl Sci. 2022; 15:2812-2837
Crossref
Scopus (2)
PubMed
Google Scholar
50.
Mousavi, SM ∙ Younesian, S ∙ Ejtahed, HS
The alteration of gut microbiota composition in patients with epilepsy: a systematic review and meta-analysis
Microb Pathog. 2025; 199, 107266
Crossref
Scopus (7)
PubMed
Google Scholar
51.
iMSMS Consortium
Gut microbiome of multiple sclerosis patients and paired household healthy controls reveal associations with disease risk and course
Cell. 2022; 185:3467-3486
Full Text
Full Text (PDF)
Scopus (96)
PubMed
Google Scholar
52.
Deng, X ∙ Gong, X ∙ Zhou, D ∙ et al.
Perturbations in gut microbiota composition in patients with autoimmune neurological diseases: a systematic review and meta-analysis
Front Immunol. 2025; 16, 1513599
Google Scholar
53.
Montgomery, TL ∙ K邦nstner, A ∙ Kennedy, JJ ∙ et al.
Interactions between host genetics and gut microbiota determine susceptibility to CNS autoimmunity
Proc Natl Acad Sci USA. 2020; 117:27516-27527
Crossref
Scopus (63)
PubMed
Google Scholar
54.
Montgomery, TL ∙ Eckstrom, K ∙ Lile, KH ∙ et al.
Lactobacillus reuteri tryptophan metabolism promotes host susceptibility to CNS autoimmunity
Microbiome. 2022; 10:198
Crossref
Scopus (52)
PubMed
Google Scholar
55.
Rebeaud, J ∙ Vigne, S ∙ Bressoud, V ∙ et al.
Gut-derived metabolites drive Th17 cell pathogenicity in multiple sclerosis
Cell Rep. 2025; 44, 116326
Full Text
Full Text (PDF)
Scopus (1)
PubMed
Google Scholar
56.
Ma, X ∙ Zhang, J ∙ Jiang, Q ∙ et al.
Human microbiome-derived peptide affects the development of experimental autoimmune encephalomyelitis via molecular mimicry
eBioMedicine. 2025; 111, 105516
Full Text
Full Text (PDF)
Scopus (0)
Google Scholar
57.
Pröbstel, AK ∙ Zhou, X ∙ Baumann, R ∙ et al.
Gut microbiota-specific IgA+ B cells traffic to the CNS in active multiple sclerosis
Sci Immunol. 2020; 5, eabc7191
Crossref
PubMed
Google Scholar
58.
Rasoulian, P ∙ Akhgarjand, C ∙ Houjaghani, H ∙ et al.
Gut dysbiosis in multiple sclerosis patients: a comparative analysis in fecal samples
Sci Rep. 2025; 15, 36009
Crossref
Scopus (3)
Google Scholar
59.
Gupta, VK ∙ Janda, GS ∙ Pump, HK ∙ et al.
Alterations in gut microbiome每host relationships after immune perturbation in patients with multiple sclerosis
Neurol Neuroimmunol Neuroinflamm. 2025; 12, e200355
Crossref
Scopus (15)
PubMed
Google Scholar
60.
de Bruijn, MAAM ∙ Leypoldt, F ∙ Dalmau, J ∙ et al.
Autoimmune encephalitis
Nat Rev Dis Primers. 2025; 11:65
Crossref
Scopus (12)
PubMed
Google Scholar
61.
Shang, H ∙ Shen, X ∙ Yu, X ∙ et al.
B-cell targeted therapies in autoimmune encephalitis: mechanisms, clinical applications, and therapeutic potential
Front Immunol. 2024; 15, 1368275
Crossref
Scopus (17)
Google Scholar
62.
Theorell, J ∙ Harrison, R ∙ Williams, R ∙ et al.
Ultrahigh frequencies of peripherally matured LGI1- and CASPR2-reactive B cells characterize the cerebrospinal fluid in autoimmune encephalitis
Proc Natl Acad Sci USA. 2024; 121, e2311049121
Crossref
Scopus (32)
PubMed
Google Scholar
63.
Wagnon, I ∙ H谷lie, P ∙ Bardou, I ∙ et al.
Autoimmune encephalitis mediated by B-cell response against N-methyl-d-aspartate receptor
Brain. 2020; 143:2957-2972
Crossref
Scopus (42)
PubMed
Google Scholar
64.
Muñoz-S芍nchez, G ∙ Guasp, M ∙ Muñoz-Lopetegi, A ∙ et al., the Anti-LGI1 encephalitis study group
Cytokine and chemokine profiles in anti-LGI1 encephalitis: markers of severity and outcome
Neurol Neuroimmunol Neuroinflamm. 2025; 12, e200492
Crossref
Scopus (3)
PubMed
Google Scholar
65.
Aboseif, A ∙ Mangioris, G ∙ Yang, B ∙ et al.
Cytokine, chemokine, and neurofilament light chain signatures in LGI1 autoimmune encephalitis
Ann Clin Transl Neurol. 2025; 12:2258-2270
Crossref
Scopus (7)
PubMed
Google Scholar
66.
Ma, X ∙ Ma, L ∙ Wang, Z ∙ et al.
Clinical features and gut microbial alterations in anti-leucine-rich glioma-inactivated 1 encephalitis〞a pilot study
Front Neurol. 2020; 11, 585977
Crossref
Scopus (14)
Google Scholar
67.
Gilbert, E ∙ Binks, S ∙ Damato, V ∙ et al.
The gut microbiome associated with LGI1-antibody encephalitis
Epilepsia. 2025; 66:4411-4424
Crossref
Scopus (2)
Google Scholar
68.
Chen, H ∙ Chen, Z ∙ Shen, L ∙ et al.
Fecal microbiota transplantation from patients with autoimmune encephalitis modulates Th17 response and relevant behaviors in mice
Cell Death Discov. 2020; 6:75
Crossref
Scopus (17)
PubMed
Google Scholar
69.
Gong, X ∙ Liu, Y ∙ Liu, X ∙ et al.
Disturbance of gut bacteria and metabolites are associated with disease severity and predict outcome of NMDAR encephalitis: a prospective case每control study
Front Immunol. 2022; 12, 791780
Crossref
Scopus (12)
Google Scholar
70.
Wei, J ∙ Zhang, X ∙ Yang, F ∙ et al.
Gut microbiome changes in anti-N-methyl-D-aspartate receptor encephalitis patients
BMC Neurol. 2022; 22:276
Crossref
Scopus (10)
PubMed
Google Scholar
71.
Steriade, C
The gut feeling behind autoimmune encephalitis
Epilepsy Curr. 2026; 26:231-233
Crossref
Scopus (0)
PubMed
Google Scholar
72.
Steriade, C ∙ Thomas, SC ∙ Xu, F ∙ et al.
Patients with status epilepticus and new-onset refractory status epilepticus display drastically altered fecal microbiomes compared to chronic epilepsy patients
Epilepsia. 2025; 66:3254-3268
Crossref
Scopus (5)
Google Scholar
73.
Guillemaud, M ∙ Chavez, M ∙ Kobeissy, F ∙ et al.
Identification of distinct biological groups of patients with cryptogenic NORSE via inflammatory profiling
Neurol Neuroimmunol Neuroinflamm. 2025; 12, e200403
Crossref
Scopus (2)
PubMed
Google Scholar
74.
Ravizza, T ∙ Scheper, M ∙ Di Sapia, R ∙ et al.
mTOR and neuroinflammation in epilepsy: implications for disease progression and treatment
Nat Rev Neurosci. 2024; 25:334-350
Crossref
Scopus (76)
PubMed
Google Scholar
75.
Kwack, DW ∙ Lee, S ∙ Lee, DH ∙ et al.
Changes in gut microbiome can be associated with abrupt seizure exacerbation in epilepsy patients
Clin Neurol Neurosurg. 2024; 246, 108556
Crossref
Scopus (9)
PubMed
Google Scholar
76.
Zhou, C ∙ Gong, S ∙ Xiang, S ∙ et al.
Changes and significance of gut microbiota in children with focal epilepsy before and after treatment
Front Cell Infect Microbiol. 2022; 12, 965471
Crossref
Scopus (7)
Google Scholar
77.
Gong, X ∙ Liu, Y ∙ Liu, X ∙ et al.
Analysis of gut microbiota in patients with epilepsy treated with valproate: results from a three months observational prospective cohort study
Microb Pathog. 2022; 162, 105340
Crossref
Scopus (20)
Google Scholar
78.
Ceccarani, C ∙ Vigan辰, I ∙ Ottaviano, E ∙ et al.
Is gut microbiota a key player in epilepsy onset? A longitudinal study in drug-naive children
Front Cell Infect Microbiol. 2021; 11, 749509
Crossref
Scopus (20)
PubMed
Google Scholar
79.
Rodrigues, VF ∙ Elias-Oliveira, J ∙ Pereira, ÍS ∙ et al.
Akkermansia muciniphila and gut immune system: a good friendship that attenuates inflammatory bowel disease, obesity, and diabetes
Front Immunol. 2022; 13, 934695
Crossref
Scopus (103)
Google Scholar
80.
Thai, K ∙ Taylor, MW ∙ Fernandes, T ∙ et al.
Topiramate alters the gut microbiome to aid in its anti-seizure effect
Front Microbiol. 2023; 14, 1242856
Crossref
Scopus (23)
PubMed
Google Scholar
81.
Riva, A ∙ Sahin, E ∙ Volpedo, G ∙ et al.
Identification of an epilepsy-linked gut microbiota signature in a pediatric rat model of acquired epilepsy
Neurobiol Dis. 2024; 194, 106469
Crossref
Scopus (21)
PubMed
Google Scholar
82.
Kebede, V ∙ Ravizza, T ∙ Balosso, S ∙ et al.
Early treatment with rifaximin during epileptogenesis reverses gut alterations and reduces seizure duration in a mouse model of acquired epilepsy
Brain Behav Immun. 2024; 119:363-380
Crossref
Scopus (9)
PubMed
Google Scholar
83.
Scott, AJ ∙ Alexander, JL ∙ Merrifield, CA ∙ et al.
International Cancer Microbiome Consortium consensus statement on the role of the human microbiome in carcinogenesis
Gut. 2019; 68:1624-1632
Crossref
Scopus (172)
PubMed
Google Scholar
84.
Barborka, CJ
Ketogenic diet treatment of epilepsy in adults
JAMA. 1928; 91:73-78
Crossref
Google Scholar
85.
Dahlin, M ∙ Wheelock, CE ∙ Prast-Nielsen, S
Association between seizure reduction during ketogenic diet treatment of epilepsy and changes in circulatory metabolites and gut microbiota composition
eBioMedicine. 2024; 109, 105400
Full Text
Full Text (PDF)
Scopus (13)
PubMed
Google Scholar
86.
Wang, Y ∙ Guo, J ∙ Zhang, P ∙ et al.
Gut microbiota signatures associated with ketogenic diet response in pediatric drug-resistant epilepsy
Seizure. 2026; 134:220-228
Full Text
Full Text (PDF)
Scopus (0)
PubMed
Google Scholar
87.
Wang, J ∙ Huang, L ∙ Li, H ∙ et al.
Effects of ketogenic diet on the classification and functional composition of intestinal flora in children with mitochondrial epilepsy
Front Neurol. 2023; 14, 1237255
Google Scholar
88.
Lum, GR ∙ Ha, SM ∙ Olson, CA ∙ et al.
Ketogenic diet therapy for pediatric epilepsy is associated with alterations in the human gut microbiome that confer seizure resistance in mice
Cell Rep. 2023; 42, 113521
Full Text
Full Text (PDF)
Scopus (2)
PubMed
Google Scholar
89.
Dahlin, M ∙ Singleton, SS ∙ David, JA ∙ et al.
Higher levels of Bifidobacteria and tumor necrosis factor in children with drug-resistant epilepsy are associated with anti-seizure response to the ketogenic diet
eBioMedicine. 2022; 80, 104061
Full Text
Full Text (PDF)
Scopus (22)
PubMed
Google Scholar
90.
Monda, A ∙ La Torre, ME ∙ Messina, A ∙ et al.
Exploring the ketogenic diet's potential in reducing neuroinflammation and modulating immune responses
Front Immunol. 2024; 15, 1425816
Crossref
Scopus (31)
PubMed
Google Scholar
91.
Cantoni, C ∙ Lin, Q ∙ Dorsett, Y ∙ et al.
Alterations of host-gut microbiome interactions in multiple sclerosis
eBioMedicine. 2022; 76, 103798
Full Text
Full Text (PDF)
Scopus (65)
PubMed
Google Scholar
92.
Özcan, E ∙ Yu, KB ∙ Dinh, L ∙ et al.
Dietary fiber content in clinical ketogenic diets modifies the gut microbiome and seizure resistance in mice
Nat Commun. 2025; 16:987
Crossref
Scopus (7)
PubMed
Google Scholar
93.
Ghezzi, L ∙ Tosti, V ∙ Shi, L ∙ et al.
Randomised controlled trial of intermittent calorie restriction in people with multiple sclerosis
J Neurol Neurosurg Psychiatry. 2025; 96:158-169
Crossref
Scopus (1)
PubMed
Google Scholar
94.
Träger, C ∙ Kaiser, M ∙ Freudenstein, D ∙ et al.
A probiotic approach identifies a Treg-centred immunoregulation via modulation of gut microbiota metabolites in people with multiple sclerosis and healthy individuals
eBioMedicine. 2025; 116, 105743
Full Text
Full Text (PDF)
Scopus (10)
PubMed
Google Scholar
95.
Zangeneh, Z ∙ Rostamian, M ∙ Motamedi, H ∙ et al.
The potential effectiveness of probiotics in reducing multiple sclerosis progression in preclinical and clinical studies: a worldwide systematic review and meta-analysis
PLoS One. 2025; 20, e0319755
Crossref
Scopus (10)
PubMed
Google Scholar
96.
Duscha, A ∙ Gisevius, B ∙ Hirschberg, S ∙ et al.
Propionic acid shapes the multiple sclerosis disease course by an immunomodulatory mechanism
Cell. 2020; 180:1067-1080
Full Text
Full Text (PDF)
Scopus (371)
PubMed
Google Scholar
97.
Shirzadi, P ∙ Farokh, P ∙ Osouli Meinagh, S ∙ et al.
The influence of the probiotics, ketogenic diets, and gut microbiota on epilepsy and epileptic models: a comprehensive review
Mol Neurobiol. 2025; 62:14519-14543
Crossref
Scopus (8)
PubMed
Google Scholar
98.
Li, H ∙ Niu, R ∙ He, W ∙ et al.
Lachnospira eligens attenuates epileptogenesis via gut每brain axis regulation of blood每brain barrier integrity and neuroinflammation
Theranostics. 2026; 16:1045-1062
Crossref
PubMed
Google Scholar
99.
Tan, K ∙ Yu, Y ∙ Liu, P ∙ et al.
Probiotics in epilepsy treatment: a meta-analysis of efficacy and safety
Front Microbiol. 2025; 16, 1676480
Google Scholar
100.
Peery, AF ∙ Kelly, CR ∙ Kao, D ∙ et al., the AGA Clinical Guidelines Committee
AGA Clinical Practice Guideline on fecal microbiota-based therapies for select gastrointestinal diseases
Gastroenterology. 2024; 166:409-434
Full Text
Full Text (PDF)
Scopus (10)
PubMed
Google Scholar
101.
Miller, CB ∙ Bader, GA ∙ Kay, CL
Fecal microbiota transplantation in 2025: two steps forward, one step back
Curr Gastroenterol Rep. 2026; 28:5
Crossref
Scopus (3)
PubMed
Google Scholar
102.
Kelly, CR ∙ Yen, EF ∙ Grinspan, AM ∙ et al.
Fecal microbiota transplantation is highly effective in real-world practice: initial results from the FMT National Registry
Gastroenterology. 2021; 160:183-192
Full Text
Full Text (PDF)
Scopus (115)
PubMed
Google Scholar
103.
Baydoun, H ∙ Hussain, N ∙ Wu, KO ∙ et al.
What's new and what's next in fecal microbiota transplantation?
Biologics. 2025; 19:481-496
PubMed
Google Scholar
104.
Matheson, JT ∙ Holsinger, RMD
The role of fecal microbiota transplantation in the treatment of neurodegenerative diseases: a review
Int J Mol Sci. 2023; 24, 1001
Crossref
Scopus (40)
PubMed
Google Scholar
105.
Wang, S ∙ Chen, H ∙ Wen, X ∙ et al.
The efficacy of fecal microbiota transplantation in experimental autoimmune encephalomyelitis: transcriptome and gut microbiota profiling
J Immunol Res. 2021; 2021, 4400428
Crossref
Scopus (35)
Google Scholar
106.
Su, SH ∙ Wu, YF ∙ Lin, Q ∙ et al.
Fecal microbiota transplantation and replenishment of short-chain fatty acids protect against chronic cerebral hypoperfusion-induced colonic dysfunction by regulating gut microbiota, differentiation of Th17 cells, and mitochondrial energy metabolism
J Neuroinflammation. 2022; 19:313
Crossref
Scopus (14)
PubMed
Google Scholar
107.
Al, KF ∙ Craven, LJ ∙ Gibbons, S ∙ et al.
Fecal microbiota transplantation is safe and tolerable in patients with multiple sclerosis: a pilot randomized controlled trial
Mult Scler J Exp Transl Clin. 2022; 8
20552173221086662
PubMed
Google Scholar
108.
Medel-Matus, JS ∙ Simpson, CA ∙ Ahdoot, AI ∙ et al.
Modification of post-traumatic epilepsy by fecal microbiota transfer
Epilepsy Behav. 2022; 134, 108860
Full Text
Full Text (PDF)
Scopus (5)
PubMed
Google Scholar
109.
Dai, Z ∙ Cheng, W ∙ Peng, H ∙ et al.
Microbiota composition-based donor selection affects FMT efficacy in a murine colitis model
Front Immunol. 2025; 16, 1635244
Crossref
Scopus (7)
Google Scholar
110.
The iMSMS Consortium
Household paired design reduces variance and increases power in multi-city gut microbiome study in multiple sclerosis
Mult Scler J. 2021; 27:366-379
Crossref
Scopus (27)
Google Scholar
111.
Ning, L ∙ Zhou, YL ∙ Sun, H ∙ et al.
Microbiome and metabolome features in inflammatory bowel disease via multi-omics integration analyses across cohorts
Nat Commun. 2023; 14, 7135
Crossref
Scopus (221)
Google Scholar
112.
Forbes, M ∙ Ng, DYK ∙ Boggan, RM ∙ et al.
Benchmarking of human read removal strategies for viral and microbial metagenomics
Cell Rep Methods. 2025; 5, 101218
PubMed
Google Scholar
113.
Agustinho, DP ∙ Fu, Y ∙ Menon, VK ∙ et al.
Unveiling microbial diversity: harnessing long-read sequencing technology
Nat Methods. 2024; 21:954-966
Crossref
Scopus (1)
PubMed
Google Scholar
114.
Kerr, WT ∙ Auvin, S ∙ Van der Geyten, S ∙ et al.
Time-to-event clinical trial designs: existing evidence and remaining concerns
Epilepsia. 2023; 64:1699-1708
Crossref
Scopus (6)
PubMed
Google Scholar
115.
Lee, ST ∙ Abboud, H ∙ Irani, SR ∙ et al.
Innovation and optimization in autoimmune encephalitis trials: the design and rationale for the phase 3, randomized study of satralizumab in patients with NMDAR-IgG-antibody-positive or LGI1-IgG-antibody-positive autoimmune encephalitis (CIELO)
Front Neurol. 2024; 15, 1437913
Crossref
Scopus (18)
Google Scholar
116.
Lopes Neri, LC ∙ Guglielmetti, M ∙ Fiorini, S ∙ et al.
Adherence to ketogenic dietary therapies in epilepsy: a systematic review of literature
Nutr Res. 2024; 126:67-87
Crossref
Scopus (5)
PubMed
Google Scholar
117.
Sorbara, MT ∙ Pamer, EG
Microbiome-based therapeutics
Nat Rev Microbiol. 2022; 20:365-380
Crossref
Scopus (185)
PubMed
Google Scholar
118.
Hoffmann, DE ∙ Javitt, GH ∙ Kelly, CR ∙ et al.
Fecal microbiota transplantation: a tale of two regulatory pathways
Gut Microbes. 2025; 17, 2493901
Crossref
Scopus (24)
Google Scholar
119.
Gihawi, A ∙ Cooper, CS ∙ Brewer, DS
Caution regarding the specificities of pan-cancer microbial structure
Microb Genom. 2023; 9, mgen001088
PubMed
Google Scholar
Related Specialty Collections[size=1.13]This article can be found in the following collections:
Figures (3)Figure Viewer[/url][url=https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(26)00193-6/abstract#fig2][/url]
Article metricsMetric data currently unavailableSupplementary material (1)[url=https://www.thelancet.com/cms/10.1016/S1474-4422(26)00193-6/attachment/8941a981-fbbb-453b-8571-c3043edba34d/mmc1.pdf]PDF (668.60 KB)Supplementary appendix
- [size=1.15][url=https://www.linkedin.com/company/the-lancet/]
- [size=1.15]
- [size=1.15][/url]
- [size=1.15]
- [size=1.15]
- [size=1.15]
- [size=1.15]
- [size=1.15]
- [size=1.15]
Lancet Journals
- [size=0.875][url=https://www.thelancet.com/journals/lancet/home]The Lancet
[size=0.875]The Lancet Child & Adolescent Health[size=0.875]The Lancet Diabetes & Endocrinology[size=0.875]The Lancet Digital Health[size=0.875]The Lancet Gastroenterology & Hepatology[size=0.875]The Lancet Global Health[size=0.875]The Lancet Haematology[size=0.875]The Lancet Healthy Longevity[size=0.875]The Lancet HIV[size=0.875]The Lancet Infectious Diseases[size=0.875]The Lancet Medical Imaging & Theranostics[size=0.875]The Lancet Microbe[size=0.875]The Lancet Neurology[size=0.875]The Lancet Obstetrics, Gynaecology, & Women's Health[size=0.875]The Lancet Oncology[size=0.875]The Lancet Planetary Health[size=0.875]The Lancet Primary Care[size=0.875]The Lancet Psychiatry[size=0.875]The Lancet Public Health[size=0.875]The Lancet Regional Health 每 Africa[size=0.875]The Lancet Regional Health 每 Americas[size=0.875]The Lancet Regional Health 每 Eastern Mediterranean[size=0.875]The Lancet Regional Health 每 Europe[size=0.875]The Lancet Regional Health 每 Southeast Asia[size=0.875]The Lancet Regional Health 每 Western Pacific[size=0.875]The Lancet Respiratory Medicine[size=0.875]The Lancet Rheumatology[size=0.875]The Lancet Surgery & Anaesthesiology[size=0.875]eBioMedicine[size=0.875]eClinicalMedicine
CLINICAL
GLOBAL HEALTH INITIATIVES
MULTIMEDIA
Information
Access
Connect
my account:
[size=0.875]
The content on this site is intended for science and health care professionals.
[size=0.875]
All content on this site: Copyright © 2026 Elsevier Ltd., its licensors, and contributors.
All rights are reserved, including those for text and data mining, AI training, and similar technologies.
For all open access content, the relevant licensing terms apply.
Privacy Policy Cookie settings Terms and Conditions Accessibility Responsible AI
[url=https://www.relx.com/][/url]
|
10
A low power SAR ADC with fine每tuned time based adaptive sampling technique for ECG monitoring application in 180nm CMOS
